- Home
- »
- Pharmaceuticals
- »
-
Uveitis Treatment Market Size & Share Report, 2026-2033GVR Report cover
Uveitis Treatment Market (2026 - 2033)
Size, Share & Trends Analysis Report By Treatment (Corticosteroids, Immunosuppressant, Monoclonal Antibodies), By Disease, By Cause, By Distribution Channel, By Region, And Segment Forecasts
Market Size, 2025
$2.7BMarket Estimate, 2026
$2.9BMarket Forecast, 2033
$5.5BCAGR, 2026–2033
9.1%Uveitis Treatment Market Summary
The global uveitis treatment market size was valued at USD 2.7 billion in 2025 and is projected to grow from USD 2.9 billion in 2026 to USD 5.5 billion by 2033, at a CAGR of 9.1% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of around 44.5% in 2025. The growth is due to the rising prevalence of uveitis, increased awareness, and early diagnosis.
Key Market Trends & Insights
- By treatment: Corticosteroids segment dominated the market, with a revenue share of around 25.5% in 2025.
- By disease: Anterior uveitis segment held the largest revenue share of around 47.0% in 2025.
- By cause: Infectious segment held the largest revenue share of over 82.0% in 2025.
- By distribution channel: Retail segment held the largest revenue share of approximately 41.0% in 2025.
Regional Insights
- Largest regional market: North America (44.5% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The U.S. held the largest market share in 2025.
Market Size & Forecast
- Market size in 2025: USD 2.7 Billion
- Estimated market size in 2026: USD 2.9 Billion
- Projected market size by 2033: USD 5.5 Billion
- CAGR (2026-2033): 9.1%
Prism AI by Grand View Research Free to tryAsk a question about the uveitis treatment marketTry asking✓Every figure cited from GVR research Prefer the report? Download free sample →The growing R&D activities in the field of ophthalmology, technological advancements, and an aging population have also propelled the market growth. Increased incidence of autoimmune conditions such as rheumatoid arthritis, lupus, and Crohn's disease is leading to a higher prevalence of uveitis. The increasing prevalence of uveitis, particularly non-infectious forms, is a primary driver for market growth. In addition, infectious etiologies such as toxoplasmosis, herpes viruses, tuberculosis, and syphilis continue to contribute significantly to the global disease burden, particularly in developing regions. A study of medical records in California found that uveitis causes blindness in a significant number of people, accounting for approximately 10% of all blindness cases. As the global population ages, there is an expected increase in age-related eye disorders, including uveitis. According to the WHO, the global population aged 60 and over will surge from 900 million in 2015 to 2 billion by 2050, representing a rapid shift from 12% to 22% of the total population.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,Download Free Sample Report
There has been a notable shift towards biologics and immunomodulatory therapies for managing uveitis. Increasing adoption of corticosteroid-sparing therapies, sustained-release intravitreal implants, and localized drug delivery technologies, such as suprachoroidal administration, is further transforming the treatment landscape. Advancements in ophthalmology diagnostic tools and techniques are enabling earlier detection of uveitis, fueling market growth. Raising awareness about uveitis and its potential complications is encouraging patients to seek medical attention sooner. The development of targeted therapies, biologics, and innovative drug delivery systems is providing more effective and convenient treatment options. Furthermore, increasing clinical trial activity, strategic collaborations, and regulatory approvals for novel ophthalmic therapies are accelerating innovation and expanding treatment options for patients with both infectious and non-infectious uveitis. Advancements in surgical interventions, including vitrectomy for selected cases with complications, are also contributing to improved patient outcomes.
Analyst Perspective
The uveitis treatment market is expected to grow steadily due to the rising prevalence of ocular inflammatory disorders, autoimmune diseases, and infectious eye diseases, along with the increasing demand for advanced ophthalmic therapies. The market is being supported by the growing adoption of biologic therapies, corticosteroid-sparing treatments, targeted immunomodulators, and sustained-release drug delivery systems that improve patient outcomes and treatment adherence. Increasing awareness regarding early diagnosis and management of uveitis, along with advancements in diagnostic technologies and expanding access to specialized ophthalmic care, is further contributing to market expansion. Pharmaceutical companies are focusing on developing targeted therapies that provide effective inflammation control while minimizing adverse effects associated with long-term steroid use.
Treatment Insights
The corticosteroids segment dominated the market with approximately 25.5% of revenue share in 2025. Corticosteroids are anti-inflammatory medications that help reduce inflammation in the eye, which is crucial for managing uveitis symptoms and preventing complications. Moreover, the increasing focus on targeted corticosteroid delivery technologies is driving collaborations aimed at improving treatment efficacy while minimizing systemic exposure in patients with uveitis. For instance, in November 2024, Santen Pharmaceutical and Arctic Vision announced a commercial collaboration agreement for ARVN001, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitic macular edema in China. The collaboration supports the commercialization of a targeted corticosteroid therapy utilizing suprachoroidal drug delivery technology, designed to enhance local drug delivery to the posterior segment while healthy surrounding ocular tissues.
The antibiotics segment is anticipated to witness the fastest CAGR over the forecast period. The increasing incidence of infectious uveitis due to pathogens such as bacteria, viruses, and fungi has significantly contributed to the rising demand for antibiotics in the treatment landscape. As awareness about infectious causes of uveitis grows among healthcare professionals, there is a corresponding increase in the prescription of antibiotics tailored to specific infections. Improved diagnostic techniques, increasing antimicrobial susceptibility testing, and growing emphasis on pathogen-specific treatment are further supporting the growth of this segment.
Disease Insights
The anterior uveitis segment dominated the market with approximately 47.0% of revenue share in 2025. This is due to the rise in autoimmune diseases, infections, and systemic inflammatory conditions that predispose individuals to this type of uveitis. Moreover, the growing awareness and advancements in diagnostic techniques have led to earlier detection and treatment of anterior uveitis cases. This heightened awareness among healthcare professionals and patients alike contributes to an increase in treatment demand. Furthermore, the aging population is more susceptible to various ocular diseases, including anterior uveitis, thereby driving market growth.
Posterior uveitis is anticipated to witness the fastest CAGR over the forecast period. The rising incidence of systemic inflammatory diseases, such as sarcoidosis and tuberculosis, is driving the increase in posterior uveitis cases. The global spread of these diseases due to factors such as urbanization and international travel has resulted in a higher incidence of posterior uveitis. Advances in imaging technologies have also improved the diagnosis of posterior uveitis, leading to more patients being identified and treated effectively.
Cause Insights
The infectious segment dominated the market with around 82.0% of revenue share in 2025. This is due to the rising incidence of infectious diseases that can lead to uveitis, such as toxoplasmosis and viral infections. Increasing awareness of infectious ocular diseases, improved diagnostic capabilities, and the timely initiation of antimicrobial and anti-inflammatory therapies are further driving growth in this segment. The growing awareness among healthcare professionals regarding the importance of early diagnosis and intervention in managing infectious uveitis is also contributing to market growth.
The non-infectious segment is anticipated to witness the fastest CAGR over the forecast period. This growth is attributed to the rising prevalence of autoimmune diseases such as rheumatoid arthritis and sarcoidosis, which are known to cause non-infectious uveitis. The increasing adoption of biologics and corticosteroid-sparing immunomodulatory therapies, along with sustained investment in the development of targeted treatments, is further supporting the growth of this segment.
Distribution Channel Insights
The retail pharmacies segment dominated the market with approximately 41.0% share in 2025 due to their widespread accessibility and convenience. Patients often rely on local pharmacies to obtain prescription medications for their conditions. The increasing number of retail pharmacy chains and their expansion into underserved areas further contribute to their market dominance. In addition, the growing prevalence of chronic ocular inflammatory diseases, increasing availability of prescription ophthalmic medications, and favorable reimbursement for outpatient therapies are supporting the growth of this segment. Moreover, retail pharmacies frequently offer patient counseling and support services, which can be valuable for patients with chronic conditions such as uveitis.
Online pharmacies are projected to grow at the fastest CAGR over the forecast period due to the growing acceptance of e-commerce in healthcare. These platforms allow patients to order medications from the comfort of their homes, often at lower prices than traditional retail pharmacies. Patients appreciate the convenience of ordering medications from home, which is especially beneficial for those with mobility issues or those living in remote areas. The increasing adoption of e-prescriptions, digital healthcare platforms, and home delivery services, along with rising internet penetration and smartphone usage, is further driving the growth of the online pharmacy segment.
Regional Insights
North America uveitis treatment market dominated the global market with 44.5% revenue share in 2025. This growth can be attributed to the region's large, aging population, which increases the risk of developing uveitis; advanced healthcare infrastructure; a well-established pharmaceutical industry; and the strong presence of leading ophthalmic pharmaceutical companies. Increasing investment in clinical research and the development of novel targeted therapies are further driving market growth. The growing focus on developing innovative steroid-free therapies for ocular inflammatory disorders is driving clinical research and expanding treatment options for patients with non-infectious uveitis. For instance, in January 2026, the U.S. FDA cleared the Investigational New Drug (IND) application for NOV05. This approval enables initiation of the EYETAC Phase II clinical trial, offering new hope to patients with non-infectious anterior uveitis. NOV05 is a steroid-free tacrolimus ophthalmic solution. This advancement highlights the growing emphasis on developing safer, targeted, and steroid-sparing therapies in North America, which is expected to increase the availability of innovative treatment options for patients with uveitis.
To learn more about this report,Download Free Sample Report
U.S. Uveitis Treatment Market Trends
The U.S. uveitis treatment market dominated the North America market in 2025. The country's robust healthcare system, coupled with a strong focus on research and development, has led to significant advancements in the diagnosis and treatment of uveitis. The presence of leading pharmaceutical companies, increasing adoption of biologics and sustained-release corticosteroid therapies, favorable reimbursement policies, and growing participation in clinical trials are further driving market growth in the country.
Europe Uveitis Treatment Market Trends
The Europe uveitis treatment market was identified as a lucrative region in 2025 due to a rising geriatric population, rising prevalence of uveitis, and growing awareness among healthcare professionals regarding the importance of early diagnosis and treatment. According to the European Commission, more than one-fifth of the European population is aged 65 years and over.
The German uveitis treatment market is expected to grow rapidly in the coming years. The country's well-developed healthcare system, coupled with a strong focus on research and innovation, has led to significant advancements in ophthalmology. The presence of key pharmaceutical companies and clinical research organizations within Germany fosters innovation and enhances access to cutting-edge therapies for patients suffering from uveitis.
Asia Pacific Uveitis Treatment Market Trends
The Asia Pacific market is anticipated to witness the fastest CAGR in the coming years. This growth is attributed to the large and growing population and the increasing prevalence of autoimmune and infectious diseases. Rising healthcare expenditure, improving access to specialized ophthalmic care, and increasing adoption of advanced immunomodulatory therapies are further driving market growth in the region. The increasing focus on expanding access to advanced ophthalmic therapies and strengthening clinical research capabilities across the Asia Pacific is supporting the development of innovative treatments for inflammatory eye disorders. These developments support the broader growth of advanced ophthalmic therapeutics and inflammatory eye disease management, thereby supporting the expansion of advanced ophthalmic therapeutics across the region for inflammatory eye disease treatment, including uveitis.
The uveitis treatment market in India held a substantial share in 2025 due to its large population, rising incidence of infectious diseases, and increasing affordability of healthcare services. Moreover, growing investment in healthcare infrastructure by both the public and private sectors is enhancing access to ophthalmic care. Increasing awareness of early diagnosis and treatment of ocular inflammatory disorders, coupled with the expansion of tertiary eye care centers, is further supporting market growth in the country.
Key Uveitis Treatment Company Insights
Some of the key companies in the uveitis treatment market are AbbVie Inc., Santen Pharmaceutical Co., Ltd., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., EyePoint, Inc., Novartis AG, Harrow, Inc., Clearside Biomedical, ANI Pharmaceuticals, Inc., UCB S.A., and others. Companies in the market are focusing on developing innovative therapies, expanding ophthalmology portfolios, securing regulatory approvals, and launching new products to strengthen their competitive position.
Harrow, Inc. is an ophthalmic pharmaceutical company focused on developing and commercializing innovative therapies for eye diseases. The company's portfolio includes TRIESENCE (triamcinolone acetonide injectable suspension), which is indicated for ocular inflammatory conditions that are unresponsive to topical corticosteroids, supporting its position in the uveitis treatment market.
Key Uveitis Treatment Companies
The following key companies have been profiled for this study on the uveitis treatment market.
-
AbbVie Inc.
-
Santen Pharmaceutical Co., Ltd.
-
Bausch Health Companies Inc.
-
Regeneron Pharmaceuticals Inc.
-
EyePoint, Inc.
-
Novartis AG
-
Harrow, Inc.
-
Clearside Biomedical
-
ANI Pharmaceuticals, Inc.
-
UCB S.A.
Recent Developments
-
In March 2025, Harrow announced a five-year strategic supply and development agreement for TRIESENCE (triamcinolone acetonide injectable suspension). The agreement ensures continued manufacturing and supports development of a next-generation formulation. TRIESENCE is indicated for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.
-
In March 2025, ANI Pharmaceuticals announced that the U.S. FDA approved an expanded indication for ILUVIEN to treat chronic non-infectious uveitis affecting the posterior segment of the eye.
Uveitis Treatment Market Report Scope
Report Attribute
Details
Market size in 2025
USD 2.7 billion
Estimated market size in 2026
USD 2.9 billion
Projected market size by 2033
USD 5.5 billion
Growth rate
CAGR of 9.1% from 2026 to 2033
Base year for estimation
2025
Actual data
2021 - 2024
Forecast period
2026 - 2033
Quantitative units
Revenue in USD billion, and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, trends
Segments covered
Treatment, disease, cause, distribution channel, region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Norway; Sweden; Japan; China; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled
AbbVie Inc.; Santen Pharmaceutical Co., Ltd.; Bausch Health Companies Inc.; Regeneron Pharmaceuticals Inc.; EyePoint, Inc.; Novartis AG; Harrow, Inc.; Clearside Biomedical; ANI Pharmaceuticals, Inc.; UCB S.A.
Customization scope
Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail of customized purchase options to meet your exact research needs. Explore purchase options
Global Uveitis Treatment Market Report Segmentation
This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global uveitis treatment market report based on treatment, disease, cause, distribution channel, and region:
-
Treatment Outlook (Revenue, USD Billion, 2021 - 2033)
-
Corticosteroids
-
Immunosuppressant
-
Monoclonal Antibodies
-
Cycloplegic Agents
-
Antibiotics
-
Antivirals
-
Antifungal
-
Analgesics
-
-
Disease Outlook (Revenue, USD Billion, 2021 - 2033)
-
Anterior Uveitis
-
Posterior Uveitis
-
Intermediate Uveitis
-
Panuveitis
-
-
Cause Outlook (Revenue, USD Billion, 2021 - 2033)
-
Infectious
-
Non-infectious
-
-
Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
-
Others
-
-
Regional Outlook (Revenue, USD Billion, 2021 - 2033)
-
North America
-
U.S.
-
Mexico
-
Canada
-
-
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
South Korea
-
Thailand
-
Australia
-
-
Latin America
-
Brazil
-
Argentina
-
-
MEA
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Frequently Asked Questions About This Report
The global uveitis treatment market size was valued at USD 2.2 billion in 2023 and is estimated at USD 2.9 billion for 2026.
The global uveitis treatment market is expected to grow at a CAGR of % from 2024 to 2030, reaching USD 4.1 billion by 2030.
North America dominated the uveitis treatment market with a share of 44.9% in 2023. This is attributable to rising prevalence of noninfectious uveitis in the U.S., advanced healthcare facilities, favorable reimbursement policies, and availability of large number of drugs in the U.S.
Some key players operating in the uveitis treatment market include AbbVie Inc., Santen Pharmaceutical Co., Ltd. , Bausch Health Companies Inc. , Regeneron Pharmaceuticals Inc., EyePoint Pharmaceuticals, Inc. , Novartis AG , Ocular Therapeutix, Inc. , Ophthotech Corporation, Pfizer Inc.
Key factors that are driving the market growth include rising incidence of uveitis, growing R&D activities in the field of ophthalmology, increasing number of clinical trials for eye inflammation treatment. With growing cases of infectious diseases, the prevalence of uveitis with infectious etiologies is also rising.
About the Author(s)
Pharmaceuticals Research Team
Healthcare · PharmaceuticalsThis report was authored by the pharmaceuticals research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the pharmaceuticals segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.